INDIANAPOLIS, Feb.
20, 2018 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY)
announced today findings from a Lilly-sponsored, quantitative
opinion survey, which found among those surveyed, people diagnosed
with migraine experienced on average 15.4 completely pain-free days
over the previous 30 days. The Migraine Impact Report also
highlighted the impact of migraine on a person's day-to-day-life,
with respondents noting the symptoms of their migraine prevented
them from doing what they wanted to do for one week (6.9 days) over
the previous 30 days.
Experience the interactive Multichannel News Release here:
https://www.multivu.com/players/English/8259051-lilly-migraine-impact-report/
The Migraine Impact Report evaluated the physical, social and
economic challenges of migraine. Respondents included 1,018 U.S.
adults, including 518 people who have been diagnosed with migraine
by a healthcare provider, 200 people who know someone with migraine
and 300 community members who do not know someone with
migraine.
Notably, the worst migraine pain ranked higher than that of
childbirth among those surveyed who had experienced both (n=244, an
average score of 8.6 compared to 7.3, on a scale of one to 10).
Respondents diagnosed with migraine on average rated the worst
migraine pain similarly to that of the "most painful thing I have
ever experienced" (8.6 compared to 8.7), and higher than both the
pain associated with kidney stones and broken bones (8.3 and 7.0,
respectively).
"As a practicing neurologist, I saw firsthand both the burden
faced by people living with this often disabling, neurological
disease, and the feeling that people must 'power through' their
lives because those around them may not understand just how
all-encompassing migraine can be," said Sheena Aurora, M.D., medical fellow, Eli Lilly
and Company.
People who do not have migraine often underestimate the pain
and average duration of migraine.
- Nearly all respondents diagnosed with migraine (91 percent)
agreed those who do not suffer from migraine do not understand the
severity of the disease.
- 62 percent of those surveyed who were diagnosed with migraine
agreed they try to hide the true impact of migraine from those at
work or at school.
- On a scale of one to 10, those surveyed who did not know
someone with migraine underestimated the pain of a typical migraine
(an average score of 6.2 compared to an average score of 7.1 given
by people diagnosed with migraine).
- On average, respondents diagnosed with migraine estimated the
length of a migraine as 10.3 hours longer than those respondents
who do not have migraine (an average score of 31 hours per migraine
compared to an average score of 20.7 hours per migraine,
respectively).
Migraine frequently adds stress and may result in less time
with family.
- Among those diagnosed with migraine, 82 percent of survey
respondents agreed it is stressful to have an unpredictable disease
like migraine.
- Respondents diagnosed with migraine missed an average of 7.4
important events in the previous year due to migraine, such as
birthdays, graduations or holiday gatherings.
- Nearly three-quarters of respondents diagnosed with migraine
(70 percent) agreed with the statement, "I've avoided making plans
because of migraine."
- Nearly three out of four parents surveyed who were diagnosed
with migraine (72 percent) agreed migraine affects their ability to
take care of their family.
- Among those surveyed with children under 13 years of age, 77
percent of people diagnosed with migraine agreed they were not able
to interact as much with their children as they wanted.
Migraine may impact a person's career potential.
- Among employed respondents diagnosed with migraine, seven out
of 10 (68 percent) agreed they have been less productive at work
due to migraine.
- More than half of respondents diagnosed with migraine (55
percent) agreed the disease has affected their career goals, and
one in three respondents diagnosed with migraine (32 percent)
agreed they have turned down opportunities at work because of
migraine, including a promotion.
- More than one-third of respondents diagnosed with migraine
agreed they have missed out on opportunities at work (39 percent)
or additional earnings potential (38 percent) because of
migraine.
Most respondents diagnosed with migraine agreed they wish
they could do more to manage their disease.
- 81 percent of respondents diagnosed with migraine agreed they
wish they could do more to manage their disease, while more than
half of those diagnosed with migraine (54 percent) agreed no matter
how hard they try, they don't feel they can manage migraine.
- Notably, nearly all those surveyed who have a family member
with migraine (90 percent) agreed they feel "helpless" when their
loved one has a migraine.
- Among those who have a close relationship with someone with
migraine, three out of four respondents (74 percent) agreed they
would like this person to seek better care or treatment for their
migraine.
"Results from the Migraine Impact Report support what physicians
who care for patients with migraine have known for many years. The
results also demonstrate the severity of this disease and the
pervasive impact migraine has on an individual's personal, family
and professional life," said Dr. Timothy R.
Smith, MD, RPh, FACP, Vice President, National Headache
Foundation. "These findings shine a spotlight on the serious need
for additional treatment options for the more than 36 million
Americans battling with migraine, many of whom lack a treatment
option that addresses their symptoms and allows them to function in
their day-to-day lives or which is tolerable for them."
For more information about migraine and resources available for
patients, such as finding a doctor in your area, visit the National
Headache Foundation website at www.headaches.org.
About the Migraine Impact Report
The Migraine Impact
Report is a 15-minute, online, quantitative opinion survey
conducted by Nielsen on behalf of Eli Lilly and Company in
May 2017. The survey was completed by
1,018 U.S. adults, including 518 people who have been diagnosed
with migraine by a healthcare provider, 200 people who know a
family member with migraine and 300 community members who do not
know someone with migraine. Data for both people diagnosed with
migraine and the general population were weighted to ensure
representation from each group. Survey respondents were not
restricted based on frequency or severity of migraine.
About Migraine
Migraine is a disabling neurological
disease characterized by recurrent episodes of severe headache, and
is often accompanied by other symptoms including nausea, vomiting,
sensitivity to light and sound, and changes in
vision.[1],[2] More than 36 million Americans have
migraine, with three times more women affected by migraine compared
to men.[3],[4] Of the approximately 40
percent of patients suffering from migraine for whom prevention is
appropriate, only 12 percent are currently receiving
therapy.[5],[6],[7] Results from the Second
International Burden of Migraine study show that side effects of
treatment play a role in this disconnect, with up to 54 percent of
respondents discontinuing migraine prevention therapy because of
side effects.[8] According to the Migraine Research Foundation,
healthcare and lost productivity costs associated with migraine are
estimated to be as high as $36
billion annually in the United
States, yet it remains under-recognized and
under-treated.4,7
About Lilly in Migraine
Lilly has been committed to
helping people suffering from migraine for over 25 years,
investigating more than a dozen different compounds for the
treatment of headache disorders. These research programs have
accelerated understanding of this disease and advanced the
development of Lilly's comprehensive late-stage development
programs studying potential treatments for the acute and preventive
treatment of migraine. Our goal is to make life better for people
with migraine by offering comprehensive solutions to prevent or
stop this disabling disease. The combined clinical, academic and
professional experience of our experts helps us to build our
research portfolio, identify challenges for healthcare providers
and pinpoint the needs of patients living with migraine and cluster
headache.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
www.lilly.com/newsroom/social-channels.
P-LLY
1Headache disorders. World Health
Organization website.
http://www.who.int/mediacentre/factsheets/fs277/en/. Accessed
December 4, 2017.
2Russo AF. Calcitonin gene-related peptide (CGRP): a new
target for migraine. Annual Review of Pharmacology and
Toxicology. 2015;55:533-552.
3Living with migraine. American Migraine Foundation
website.
https://americanmigrainefoundation.org/living-with-migraines/.
Accessed December 4, 2017.
4Migraine facts. Migraine Research Foundation website.
http://migraineresearchfoundation.org/about-migraine/migraine-facts/.
Accessed December 4, 2017.
5Lipton RB, Bigal ME, Diamond M, et al.; for the aMPP
Advisory Group. Migraine prevalence, disease burden and the need
for preventive therapy. Neurology. 2007;68(5):343-349.
6Lafata, JE, Tuniceli O, Cerghet M, et al. The use of
migraine preventive medications among patients with and without
migraine headaches. Cephalalgia. 2010;30(1):97-104.
7Diamond S, Bigal ME, Silberstein S, et al. Patterns of
diagnosis and acute and preventive treatment for migraine in
the United States: results from
the American Prevalence and Prevention study. Headache.
2007;47(3):355-363.
8Katic B, Rajagopalan S, Ho TW, et al. Triptan
persistency among newly initiated users in a pharmacy claims
database. Cephalalgia. 2011;31(4):488-500.
Refer to:
Jen Dial;
dial_jennifer_kay@lilly.com; +1-317-220-1172 (media)
Kevin Hern; hern_kevin_r@lilly.com;
+1-317-277-1838 (investors)
View original
content:http://www.prnewswire.com/news-releases/survey-reveals-many-people-with-migraine-live-with-pain-nearly-half-of-every-month-300599979.html
SOURCE Eli Lilly and Company